Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Enrollment of PD and PS cohorts is complete. Currently enrolling only confirmed RBD and Controls.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1- RBD | polysomnographically diagnosed RBD patients. RBD is a sleep disorder diagnosed by a sleep lab in which the individual has muscle movements during the phase of deep sleep during which the muscles should be relaxed. Suspicion of RBD by history will be confirmed during screening. | ||
| 2 - control | control:
|
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Identify the key cognitive and non-motor characteristics for early PD diagnosis | periodically performed set of clinical and imaging parameters suspected to be linked to PD to see if, as a group, these parameters could identify those at risk for motor symptoms of PD before these symptoms develop. | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Further characterize the sleep behavior patterns, olfactory function, and neurologic assessments of subjects longitudinally, over 5 years, within each group of patients. | perform baseline sleep study, olfactory testing and clinical neurologic exam followed by periodically performed set of clinical parameters. | 5 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
a A diagnosis of any non-Parkinsonian Neurodegenerative Disease.
b. Any unstable or uncontrolled medical or psychiatric condition.
c. Parasomnia or RBD not idiopathic, eg., secondary to metabolic derangement or medicine effect.
d. Renal (creatinine over 1.6) or hepatic insufficiency (LFT significantly out of range), or a history of significant uncontrolled cardiac disease.
e. Significant dementia (MMSE<25 of 30 or MOCA<25/30) that would interfere with study procedures or informed consent.
f. Any reason which, in the opinion of the PI, would increase the risk or decrease the value of any study procedure.
g. fMRI will not be performed for anyone for whom the screening questionnaire indicates is ineligible for MRI imaging.
Not provided
Not provided
Patients with polysomnographically-documented RBD, non-neurodegenerative diagnosis Age and gender matched non-RBD diagnosis, non-neurodegenerative diagnosis idiopathic PD diagnosis atypical PD diagnosis
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mya C Schiess, MD | The University fo texas Health Science Center at Houston | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of texas Health Science Center at Houston | Houston | Texas | 77030 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020187 | REM Sleep Behavior Disorder |
| D010300 | Parkinson Disease |
| D020734 | Parkinsonian Disorders |
| ID | Term |
|---|---|
| D020923 | REM Sleep Parasomnias |
| D020447 | Parasomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
blood (serum)
| functional MRI of the brain and eye tracking testing, identification of distinct features in PD |
Perform fMRI at baseline and at 2 years followed by periodically performed set of clinical parameters. |
| beginning of study and at 2 years |
| identify key fluid-based PD-associated molecular markers that identify disease state or progression | parameters within blood may be present & measurable well before motor symptoms of PD are seen. | 5 years |
| D001523 |
| Mental Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |